News and Trends 27 Jun 2018 International Fund Raises €300M for Dementia Research The Dementia Discovery Fund has raised $350M (€300M) to support industrial and academic scientists doing early-stage research to develop new dementia medicines. Launched in 2015, the Dementia Discovery Fund (DDF) is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a […] June 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 29 May 2018 Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done? With no drugs that can stop the progression of the disease and hundreds of clinical trials failing, new fields of research bring hope to people with Alzheimer’s. As the Western population ages, Alzheimer’s disease is becoming one of the biggest diseases of the 21st century. But despite the efforts of science, the FDA and EMA […] May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 18 May 2018 New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other similar conditions. The therapy (BN201) is the first its class and if successful in clinical trials will be the only treatment that can help repair […] May 18, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 Fundraising Boosts Italian Red Blood Cell Therapy EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 Oxford Firm Develops Better Test for ALS Diagnosis Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […] March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Mar 2018 Early Research in Bone Marrow Transplants Could Treat ALS Early stage research from Spain could lead to a treatment for amyotrophic lateral sclerosis (ALS) using adult stem cells from bone marrow to stop progressive muscle paralysis. Researchers from the Neuroscience Institute at the Universidad Miguel Hernández (UMH) in Elche, Alicante, and the Spanish National Research Council (CSIC) aim to test a stem cell treatment for […] March 19, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 16 Mar 2018 This Belgian Biotech Could Speed Up Diagnoses for Neurodegenerative Diseases Today we’re in Ghent, Belgium, home to several successful biotechs, including Ablynx, to visit ADx Neurosciences. The biotech specializes in biomarker assays for the detection of neurodegenerative diseases. Mission: Founded in 2011, ADx Neurosciences focuses on the development of antibodies to detect biomarkers in the diagnosis of neurodegenerative conditions from Alzheimer’s and Parkinson’s to traumatic brain injury. The anitbodies […] March 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2018 A Flick of a Switch Can Cause Age-Related Brain Deterioration Switching certain genes on or off causes the premature aging of stem cells that repair the brain. Identifying them could provide a target for new therapeutic approaches against neurodegenerative diseases. Scientists at the Babraham Insitute in Cambridge and the University of Sapienza in Rome have identified a number of genes involved in the aging of […] March 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer’s. Syndesi Therapeutics will use of Belgian biotech UCB’s expertise in drug discovery for neurological conditions to develop new therapies in cognitive disorders using a new […] February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug Sobi will enter the clinic after the Investigational New Drug application for its rare metabolic disorder candidate was accepted by the FDA. The Swedish Orphan Biovitrum (Sobi) will begin clinical trials for SOBI003, its candidate for the rare metabolic disorder, Sanfilippo syndrome type A. This was made possible as the FDA’s accepted the company’s Investigational New Drug […] January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email